

Are next-generation sequencing results knocking on Heaven's door for transplantation planning in chronic myelomonocytic leukemia?

Guillermo F. Sanz,^{1,2,3,4} Mariam Ibañez^{1,2,4,5} and Elvira Mora^{1,2}

¹Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia; ²Instituto de Investigación Sanitaria La Fe, Valencia

³Department of Medicine, University of Valencia, Valencia; ⁴Centro de Investigación Biomédica en Red de Cáncer, CIBERONC,

Instituto de Salud Carlos III, Madrid and ⁵Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Valencia, Spain

E-mail: GUILLERMO SANZ - sanz_gui@gva.es

doi:10.3324/haematol.2019.240853

Chronic myelomonocytic leukemia (CMML) is a heterogeneous malignant myeloid disorder included in the 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia in the category of myelodysplastic syndromes/myeloproliferative neoplasms. CMML patients show a diverse biological, clinical picture and heterogeneous prognosis, with short overall survival (OS) and increased risk of progression to acute myeloid leukemia. The diagnosis of CMML requires a monocytosis, defined as an absolute monocyte count above $1 \times 10^9/L$ that should represent $>10\%$ of the white blood count (WBC) differential, which persists for more than 3 months and for which other causes of reactive monocytosis have been excluded. The current World Health Organization classification includes three CMML groups, divided on the basis of blast counts, for better prognostication: CMML-0 [$<2\%$ peripheral blood (PB) and $<5\%$ bone marrow (BM) blasts]; CMML-1 (2-4% PB and/or 5-9% BM blasts); and CMML-2 (5-19% PB and/or 10-19% BM blasts). The classical French-American-British classification, still widely used, divides CMML into so-called “dysplastic” CMML (WBC $\leq 13 \times 10^9/L$) and “myeloproliferative” CMML (WBC $>13 \times 10^9/L$).

Cytogenetic abnormalities and somatic mutations are found in, respectively, 25-30% and up to 95% of CMML patients and both have a strong influence on OS. The validated CMML-specific cytogenetic risk classification recognizes three risk categories: low-risk (normal karyotype or loss of the Y chromosome as a single anomaly; $\sim 78\%$), high-risk (trisomy 8 or abnormalities of chromosome 7, or complex karyotype; $\sim 12\%$), and intermediate-risk (all other abnormalities; $\sim 9\%$).¹ The most frequently mutated genes in CMML affect epigenetic regulation and DNA methylation (*ASXL1* and *TET2*), RNA splicing (*SRSF2*), and transcription (*RUNX1*) and signaling pathways (*RAS*).^{2,4} Frameshift and nonsense *ASXL1* mutations confer an adverse prognosis,^{2,4} aggravated when *EZH2* and *ASXL1* mutations co-occur.⁵ *DNMT3A* and *TP53* mutations, although less common in CMML, have also been associated with poorer OS.^{6,7} It is noteworthy that the number of mutations also influences patients' outcomes, as recently demonstrated in a study in which a shorter OS was observed in CMML patients with three or more concomitant mutations.⁷

Specific prognostic scoring systems for individual risk assessment are essential in order to provide risk-adapted treatment. The most commonly used are the CMML-specific prognostic scoring system (CPSS),⁸ the MD Anderson Cancer Center prognostic score (MDAPS)⁹ and

the revised International Prognostic Scoring System (IPSS-R)¹⁰ (the last only being applicable to “dysplastic” CMML). More recent scoring systems that also include somatic mutations are those by the *Groupe Français des Myélodysplasies* (GFM),² the Mayo Clinic³, and the molecular CPSS.⁴ All these molecular prognostic scoring systems consider *ASXL1* mutations; the molecular CPSS also takes into account mutations in *NRAS*, *SETBP1*, and *RUNX1*.

Allogeneic hematopoietic cell transplant (HCT) is the only potentially curative therapy for patients with CMML but the number of transplant-eligible patients is low because of these individuals' advanced age, comorbidities, and frailty. A recent multicenter retrospective study with 1,656 CMML patients of whom 89 received an allogeneic HCT demonstrated the benefit of HCT for patients with higher-risk disease as determined by the CPSS¹¹ and multiple retrospective studies have documented a 3-year OS rate of 30-40%.¹²⁻¹⁵ For high-risk transplant-ineligible and/or lower-risk patients the most widely used therapies are hydroxyurea, hypomethylating agents, and best supportive care. Recent evidence suggests that hypomethylating agents might be superior to hydroxyurea.¹¹

Many studies have evaluated the prognostic factors for transplantation outcomes in CMML patients, with contradictory results.¹⁶ As would be expected, patients transplanted in complete remission¹³ as well as those with $<5\%$ blasts at transplantation¹⁴ had better outcomes in comparison to those with more advanced disease at transplantation. The favorable effect of using hypomethylating agents before transplantation over intensive chemotherapy is debatable.¹⁴⁻¹⁶ In a large study by the Center for International Blood and Marrow Transplantation Research (CIBMTR), the CPSS score at the time of HCT strongly influenced OS after transplantation.¹⁵ Table 1 shows the predictive factors for increased relapse or reduced OS evidenced in major studies on allogeneic HCT for CMML.

In this issue of *Haematologica*, Woo and colleagues, analyze long-term outcomes after allogeneic HCT in 129 patients with CMML from a single institution and evaluate clinical and molecular risk factors associated with outcomes.¹⁷ Of note, this study is the first to evaluate the impact of somatic mutations determined by next-generation sequencing (NGS) on allogeneic HCT outcomes in a large and homogeneous series of patients from a single institution. In a subcohort of 52 patients in whom a NGS panel of 75 genes was used, 85% of patients had at least one mutation, congruent with previous reports on

Table 1. Predictive factors for overall survival after allogeneic hematopoietic cell transplantation in relevant series of patients with chronic myelomonocytic leukemia.

	EBMT {Symeonidis:2015 ¹³ }	MDACC {Kongtim:2016 ¹⁴ }	CIBMTR {Liu:2017 ¹⁵ }	FHCRC {Woo:2019 ¹⁷ }
Study period	1988-2009	1991-2013	2001-2012	1986-2017
N. of patients	513	83	209	129
Median age, years (range)	53 (18-75)	57 (18-78)	57 (23-74)	55 (7-74)
Disease at HCT (CMML/AML, %)	56 / 44	57 / 43	100 / 0	71 / 29
Factors predicting OS				
Complete remission at HCT	Favorable	Favorable	NA	No effect
Higher-risk categories by CPSS/MDAPS	NA	NA	Unfavorable/NA	Unfavorable/Unfavorable
Performance Status (KPS \geq 90)	NA	No effect	Favorable	NA
HCT-CI \geq 4	NA	NA	NA	Unfavorable
High-risk CMML-specific cytogenetics	No effect	No effect	NA	Unfavorable
Graft source (peripheral blood)	No effect	NA	Favorable	No effect
Transplant from matched related donors	No effect	Favorable	NA	No effect
Prior HMA treatment	No effect	Favorable	No effect	No effect
Molecular profile	NA	NA	NA	Increased relapse: - Mutations in NRAS, ATRX, WT1 - \geq 10 gene mutations - \geq 4 mutations in epigenetic regulators
Conditioning intensity	No effect	No effect	NA	No
Development of chronic GvHD	No effect	Favorable	NA	NA
Age	No effect	No effect	NA	No effect
Year of transplant	No effect	No effect	NA	No effect

EBMT: European Society for Blood and Marrow Transplantation; MDACC: MD Anderson Cancer Center; CIBMTR: Center for International Blood and Marrow Transplantation Research; FHCRC: Fred Hutchinson Cancer Research Center; HCT: hematopoietic cell transplant; CMML: chronic myelomonocytic leukemia; AML: acute myeloid leukemia; OS: overall survival; CPSS: CMML-specific prognostic scoring system; MDAPS: MD Anderson prognostic scores; KPS: Karnofsky Performance Score; HCT-CI: Hematopoietic Cell Transplant-Comorbidity Index; PB: peripheral blood; HMA: hypomethylating agents, GvHD: graft-versus-host disease; NA: information not available.;

CMML. The most commonly mutated genes were *ASXL1* (52%), *TET2* (42%), and *SRSF2* (25%). Other frequently encountered mutations were evident for *WT1* (27%), *RUNX1* (17%), *DNMT3A* (17%), *SMC1A* (17%), *EZH2* (12%), and *ATRX* (12%), highly likely because most patients had intermediate-2 or high-risk disease according to the CPSS.¹⁷

In the study by Woo *et al.*, mutations in *NRAS* were associated with an increased relapse risk whereas mutations in *ATRX* and *WT1*, conferred both a higher relapse risk and inferior OS. Moreover, this study showed that a high overall mutation burden (\geq 10 mutations) as well as the presence of four or more mutated epigenetic regulatory genes were linked to a higher risk of relapse. Unsupervised clustering revealed two higher-risk groups with specific associations between mutations and clinical features. The presence of a higher mutation burden was closely related to a longer period between diagnosis and transplantation but not with complex chromosomal abnormalities or an excess of blasts. The currently published recommendation of an international expert panel is to use the CPSS for considering a patient as a candidate for allogeneic HCT and to transplant those CMML patients belonging to the intermediate-2/high CPSS risk groups.¹⁸ Whether the better outcomes observed with lower CPSS scores and the lower mutational burden observed in less advanced disease could argue in favor of

transplanting patients with CMML earlier in the course of their disease (e.g., extending transplantation to patients with intermediate-1 CPSS risk score) is debatable and can only be properly answered by a carefully designed study.

As previously reported in other HCT series on CMML, in the study by Woo *et al.*, relapse risk was also significantly associated with adverse cytogenetics, higher-risk CPSS and MDAPS scores, and measurable residual disease by cytogenetics at transplantation. A higher mortality was seen in patients with high-risk cytogenetics and a high HCT Comorbidity Index. Of interest, neither disease status at transplantation (complete remission vs. non-complete remission) nor pre-transplant therapy (intensive chemotherapy or hypomethylating agents) nor conditioning intensity had a clear and independent impact on transplant outcomes. Additionally, the year of transplant did not affect the risk of relapse or OS, clearly indicating that newer transplant strategies are needed to improve those outcomes.¹⁷

In summary, this study has identified both clinical and novel molecular risk factors for outcomes after allogeneic HCT that add relevant information which could be taken into account when planning transplantation for CMML patients. Table 2 illustrates the clinical and molecular risk factors for allogeneic HCT outcome in CMML patients, among whom different groups of higher-risk patients amenable to transplantation can be detected at different

Table 2. Schematic representation of the relationships between clinical and hematologic characteristics, cytogenetics, somatic mutations, prognostic scoring systems and transplant outcomes in patients with chronic myelomonocytic leukemia.

	FEATURES														
	Prognostic Scoring System		Mutational Burden		Age	ECOG & PS	Peripheral Counts			Bone Marrow Blasts		Cytogenetics			
	CPSS score Higher-risk	MDAPS score Higher-risk	≥10 total mutations	≥4 mutations in epigenetic modifying genes	> 60 years	2 - 3	RBC transfusion dependence and / or low Hb	High WBC counts (x 10 ⁹ /L)		Low platelet count	Excess of Blasts (%)		High-Risk		
							> 13	>20		5 - 10	> 10	Trisomy 8	Complex karyotype (>2)	Abn chr 7	
CPSS score 															
MDAPS score 															
Mutational Profiling 															
Delayed time from Diagnosis to HCT															
Overall Survival															
Relapse Risk after HCT															

ECOG: Eastern Cooperative Oncology Group; PS: Performance Status; CPSS: CMML-specific prognostic scoring system; MDAPS: MD Anderson prognostic score; RBC: red blood cells; Hb: hemoglobin; WBC: white blood cells; Abn: abnormalities; Chr: chromosome; HCT: hematopoietic cell transplant

time points of the course of the disease.

However, even though NGS studies could therefore be used to select a group of high-risk CMML patients for transplantation, our view is that it might still be premature to incorporate the results of NGS techniques into the decision-making process for CMML patients undergoing allogeneic HCT. The main reasons are that NGS techniques and results are not well standardized, their reproducibility is unproven, the characterization of allele variants as pathogenic is not homogeneously defined, and the variant allele frequency threshold used to define the presence of mutations is widely variable (5% in the series by Woo *et al.*) Furthermore, the impact of co-occurring mutations on prognosis is still unclear.¹⁹ Additionally, the value of molecular profiling for treatment decision-making in CMML patients is diminished by the limited number of treatment alternatives and because there is no single somatic mutation that favors the use of a particular treatment approach.¹⁹

In conclusion, molecular profiling will likely emerge in the near future as highly valuable for planning transplantation in CMML patients, adding up to other well-recognized patient and disease characteristics such as higher-risk CPSS and MDAPS categories and HCT-Cormorbidity Index. Prospective cooperative studies focused on NGS

results before and after transplantation and involving large numbers of patients will be eventually required to improve the cure rate afforded by allogeneic HCT in CMML.

Acknowledgments

This study was supported by research funding from Innovative Medicines Initiative 2 Joint Undertaking under HARMONY grant agreement n. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Program and EFPIA; FEDER funds (CIBERONC (CB16/12/00284)), "Fundación Española de Hematología (FEHH)"; "Instituto de Salud Carlos III" grants PI16/011113, PI16/00665, and PI18/01472; and from the "Consellería de Educación, Cultura y Deporte" PROMETEOII/2015/008 and GVA/2018/004.

References

- Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. *Haematologica*. 2011;96(3):375-383.
- Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. *J Clin Oncol*. 2013;31(19):2428-2436.
- Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 muta-

- tions and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. *Leukemia*. 2014;28(11):2206-2212.
4. Elena C, Galli A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. *Blood*. 2016;128(10):1408-1417.
 5. Patnaik MM, Vallapureddy R, Lasho TL, et al. EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. *Blood Cancer J*. 2018;8(1):12.
 6. Patnaik MM, Barraco D, Lasho TL, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. *Am J Hematol*. 2017;92(1):56-61.
 7. Montalban-Bravo G, Takahashi K, Patel K, et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. *Oncotarget*. 2018;9(11):9714-9727.
 8. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. *Blood*. 2013;121(15):3005-3015.
 9. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. *Blood*. 2002;99(3):840-849.
 10. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. 2012;120(12):2454-2465.
 11. Pleyer L, Leisch M, Kourakli A, et al. Effects of the therapeutic armamentarium on survival and time to next treatment in CMML subtypes: an international analysis of 950 cases coordinated by the AGMT study group. *Blood*. 2019;134(Suppl 1):844-844.
 12. Park S, Labopin M, Yakoub-Agha J, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. *Eur J Haematol*. 2013;90(5):355-364.
 13. Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Trans. *Br J Haematol*. 2015;171(2):239-246.
 14. Kongtim P, Popat U, Jiménez A, et al. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia. *Biol Blood Marrow Transplant*. 2016;22(1):47-53.
 15. Liu HD, Ahn KW, Hu Z-H, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. *Biol Blood Marrow Transplant*. 2017;23(5):767-775.
 16. Sanz GF. A Lot to learn about allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. *Biol Blood Marrow Transplant*. 2017;23(5):713-714.
 17. Woo J, Ro Choi D, Storer BE, et al. Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. *Haematologica*. 2020;105(3):652-660.
 18. de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. *Blood*. 2017;129(13):1753-1762.
 19. Sanz GF, Ibáñez M, Such E. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? *Blood Adv*. 2019;3(21):3454-3460.

Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification

Katherine L. B. Knorr and Aaron D. Goldberg

Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

E-mail: AARON D. GOLDBERG - goldbera@mskcc.org

doi:10.3324/haematol.2019.241117

The majority of patients with acute myeloid leukemia (AML) will die of their disease. Nevertheless, the prognosis of AML varies widely. Some AML patients may be cured by chemotherapy alone, while others require approaches such as allogeneic stem cell transplantation to have the best chance of long-term survival. As physicians, we are often asked by our AML patients: “How likely is this treatment going to work, and how long do I have to live?”¹

Prognostication in AML has evolved over time. Initially, models for prediction of response to therapy were based on patient’s parameters such as age and performance status in combination with cell characteristics such as morphology and chromosomal karyotype. With technological advancements, our understanding of disease biology has evolved and factors including molecular mutations and minimal residual disease have been integrated into prognostication schemes. Recently, an international expert panel on behalf of the European LeukemiaNet (ELN) published a revised version of a widely utilized prognostication scheme that categorizes AML patients into three risk groups (Favorable, Intermediate, and Adverse) based on genetic abnormalities (incorporating chromosomal karyotype and specific molecular muta-

tions).² These AML risk groups have profound clinical implications, particularly with regard to post-remission therapy for younger fit patients. In general, fit Favorable-risk AML patients who achieve a first complete remission after induction chemotherapy go on to consolidation chemotherapy with curative intent. However, even fit patients with Adverse- and Intermediate-risk AML are unlikely to be cured by chemotherapy alone, and therefore it is reasonable to consider allogeneic stem cell transplantation for Intermediate- and Adverse-risk patients upon achievement of first complete remission.

Why is AML so often resistant to chemotherapy? The biology of AML chemoresistance is complex. However, at a basic level, adverse-risk AML cells are more likely to evade conventional chemotherapeutics that target the cell cycle. It has therefore been hypothesized that one powerful driver of adverse prognosis in AML may be the properties of the leukemia stem cell (LSC), a type of cell that exhibits cell cycle quiescence, self-renewal, and chemoresistance.³⁻⁶ Although AML LSC remain challenging to isolate, assessment of AML LSC gene expression signatures has been proposed as a method to further refine prognosis – with LSC-like AML phenotypes contributing to adverse risk.